

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*Complete if Known*

Application Number	10/559,649
Filing Date	December 5, 2005
First Named Inventor	Kandiah JEYASEELAN
Group Art Unit	1754
Examiner Name	
Confirmation No.	5098
Attorney Docket Number	3240-109


[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

<p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> 				<i>Complete if Known</i>	
				Application Number	10/559,649
				Filing Date	December 5, 2005
				First Named Inventor	Kandiah JEYASEELAN
				Group Art Unit	1754
				Examiner Name	
				Confirmation No.	5098
Sheet	2	of	4	Attorney Docket Number	3240-109

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	AD	WO	99/18952		Brigham & Women's Hospital, Inc. and The General Hospital Corporation	04-22-1999	
Examiner Signature					Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	10/559,649
				Filing Date	December 5, 2005
				First Named Inventor	Kandiah JEYASEELAN
				Group Art Unit	1754
				Examiner Name	
				Confirmation No.	5098
Sheet	3	of	4	Attorney Docket Number	3240-109

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AE	BROWN, M.S., et al., "Scavenger cell receptor shared," <i>Nature</i> , August 22, 1985, pp. 680-681, Vol. 316.	
	AF	BROWN, M.S., et al., "A Receptor-Mediated Pathway for Cholesterol Homeostasis," <i>Science</i> , April 4, 1986, pp. 34-47, Vol. 23.	
	AG	BROWN, W.V., et al., "Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial," <i>American Heart Journal</i> , December 2002, pp. 1036-1043, Vol. 144, No. 6.	
	AH	COHEN, L.H. et al., "Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes," <i>Biopharm Drug Dispos</i> , Dec. 2000, pp. 353-364, vol. 21, no. 9. (Abstract)	AB
	AI	ENDO, A., et al., "Competitive Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase by ML-236A and ML-236B Fungal Metabolites, Having Hypocholesterolemic Activity," <i>FEBS Letters</i> , December 1976, pp. 323-326, vol. 72, no. 2.	
	AJ	FELESZKO, W., et al., "Lovastatin and Tumor Necrosis Factor- $\alpha$ Exhibit Potentiated Antitumor Effects Against Ha-ras-Transformed Murine Tumor Via Inhibition of Tumor-Induced Angiogenesis," <i>Int. J. Cancer</i> , 1999, pp. 560-567, vol. 81. Wiley-Liss, Inc.	
	AK	JONES, M.K., et al., "Activation of VEGF and Ras Genes In gastric mucosa during angiogenic response to ethanol injury," <i>Am. J. Physiol.</i> , 1999, pp. G-1345-G1355, vol. 276.	
	AL	KONG, D., et al., "The Anti-Angiogenic Effects of HMGCoA Reductase Inhibitors: A New Role for RhoA GTPase in the Regulation of Angiogenesis," <i>Circulation</i> , 1999, pp. 1-39, vol. 100, no. 18. Abstract #194.	AB
	AM	LIAO, J.K., "Isoprenoids as mediators of the biological effects of statins," <i>J. Clin. Invest.</i> , August 2002, pp. 285-288, vol. 110, no. 3.	
	AN	NEZASA, K., et al., "Liver-Specific Distribution Of Rosuvastatin In Rats: Comparison With Pravastatin And Simvastatin," <i>Drug Metab Dispos</i> , 2002, pp. 1158-1163, vol. 30, no. 11. The American Society for Pharmacology and Experimental Therapeutics.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	10/559,649
				Filing Date	December 5, 2005
				First Named Inventor	Kandish JEYASEELAN
				Group Art Unit	1754
				Examiner Name	
				Confirmation No.	5098
Sheet	4	of	4	Attorney Docket Number	3240-109

AO	SERAJUDDIN, A.T.M., et al., "Relative Lipophilicities, Solubilities, and Structure-Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin," <i>J. Pharm. Sci.</i> , 1991, pp. 830-834, vol. 80, no. 9.	
AP	TAKEMOTO, M., et al., "Pleiotropic Effects Of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 2001, pp. 1712-1719, vol. 21, no. 11. American Heart Association.	
AQ	VAUGHAN, C.J., "Prevention of Stroke and Dementia with Statins: Effects Beyond Lipid Lowering," <i>Am. J. Cardiol.</i> , February 20, 2003, pp. 23B-29B, vol. 91 (suppl), no. 4A. Excerpta Medica, Inc.	
Examiner Signature	/Satyanarayan Gudibande/	Date Considered
		07/16/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./